Alterations in Peripheral Metabolites as Key Actors in Alzheimer’s Disease-Reference-Cited by-同舟云学术

Alterations in Peripheral Metabolites as Key Actors in Alzheimer’s Disease

Published:2023-06 Issue:6 Volume:20 Page:379-393
ISSN:1567-2050
Container-title:Current Alzheimer Research
language:en
Short-container-title:CAR

Author:

Sheng Can¹^ORCID,Chu Xu¹,He Yan¹,Ding Qingqing¹,Jia Shulei²,Shi Qiguang¹,Sun Ran¹,Song Li¹,Du Wenying³,Liang Yuan⁴,Chen Nian⁴,Yang Yan¹,Wang Xiaoni⁵

Affiliation:

1. Department of Neurology, The Affiliated Hospital of Jining Medical University, Jining, 272000, China

2. Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China

3. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China

4. Department of Clinical Medicine, Jining Medical University, Jining, 272067, China

5. Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310020, China

Abstract

Abstract: Growing evidence supports that Alzheimer’s disease (AD) could be regarded as a metabolic disease, accompanying central and peripheral metabolic disturbance. Nowadays, exploring novel and potentially alternative hallmarks for AD is needed. Peripheral metabolites based on blood and gut may provide new biochemical insights about disease mechanisms. These metabolites can influence brain energy homeostasis, maintain gut mucosal integrity, and regulate the host immune system, which may further play a key role in modulating the cognitive function and behavior of AD. Recently, metabolomics has been used to identify key AD-related metabolic changes and define metabolic changes during AD disease trajectory. This review aims to summarize the key blood- and microbial-derived metabolites that are altered in AD and identify the potential metabolic biomarkers of AD, which will provide future targets for precision therapeutic modulation.

Funder

National Natural Science Foundation of China

Science and Technology Development Plan Project of Shandong Medical and Health

Doctoral Research Fund Project in the Affiliated Hospital of Jining Medical University

Publisher

Bentham Science Publishers Ltd.

Subject

Neurology (clinical),Neurology

Reference130 articles.

1. Jia L.; Quan M.; Fu Y.; Zhao T.; Li Y.; Wei C.; Tang Y.; Qin Q.; Wang F.; Qiao Y.; Shi S.; Wang Y.J.; Du Y.; Zhang J.; Zhang J.; Luo B.; Qu Q.; Zhou C.; Gauthier S.; Jia J.; Dementia in China: Epidemiology, clinical management, and research advances. Lancet Neurol 2020,19(1),81-92

2. Jack C.R.; Bennett D.A.; Blennow K.; Carrillo M.C.; Dunn B.; Haeberlein S.B.; Holtzman D.M.; Jagust W.; Jessen F.; Karlawish J.; Liu E.; Molinuevo J.L.; Montine T.; Phelps C.; Rankin K.P.; Rowe C.C.; Scheltens P.; Siemers E.; Snyder H.M.; Sperling R.; Elliott C.; Masliah E.; Ryan L.; Silverberg N.; NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018,14(4),535-562

3. Scheltens P.; De Strooper B.; Kivipelto M.; Holstege H.; Chételat G.; Teunissen C.E.; Cummings J.; van der Flier W.M.; Alzheimer’s disease. Lancet 2021,397(10284),1577-1590

4. Dubois B.; Hampel H.; Feldman H.H.; Scheltens P.; Aisen P.; Andrieu S.; Bakardjian H.; Benali H.; Bertram L.; Blennow K.; Broich K.; Cavedo E.; Crutch S.; Dartigues J.F.; Duyckaerts C.; Epelbaum S.; Frisoni G.B.; Gauthier S.; Genthon R.; Gouw A.A.; Habert M.O.; Holtzman D.M.; Kivipelto M.; Lista S.; Molinuevo J.L.; O’Bryant S.E.; Rabinovici G.D.; Rowe C.; Salloway S.; Schneider L.S.; Sperling R.; Teichmann M.; Carrillo M.C.; Cummings J.; Jack C.R.; Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 2016,12(3),292-323

5. Sheng C.; Yang K.; He B.; Du W.; Cai Y.; Han Y.; Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: A cross-sectional analysis from the SILCODE study. Alzheimers Res Ther 2022,14(1),35